1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. XOMA Corporation
  6. Summary
    XOMA   US98419J2069

XOMA CORPORATION

(XOMA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
18.07(c) 18.35(c) 17.87(c) 17.26(c) 17.17(c) Last
30 429 41 789 40 959 35 421 35 666 Volume
+1.18% +1.55% -2.62% -3.41% -0.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 20,8 M - -
Net income 2022 -3,51 M - -
Net Debt 2022 - - -
P/E ratio 2022 -46,0x
Yield 2022 -
Sales 2023 24,5 M - -
Net income 2023 0,40 M - -
Net Debt 2023 - - -
P/E ratio 2023 -143x
Yield 2023 -
Capitalization 196 M 196 M -
Capi. / Sales 2022 9,43x
Capi. / Sales 2023 8,01x
Nbr of Employees 12
Free-Float 94,7%
More Financials
Company
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. It also acquires the economics associated with pre-commercial therapeutic candidates that are licensed... 
Sector
Biotechnology & Medical Research
Calendar
05/25 | 10:00amPresentation
More about the company
Ratings of XOMA Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about XOMA CORPORATION
05/19XOMA CORP : Change in Directors or Principal Officers, Submission of Matters to a Vote of ..
AQ
05/17XOMA to Present at H.C. Wainwright Global Investment Conference
AQ
05/05XOMA CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF O..
AQ
05/05XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05XOMA : Q1 Earnings Snapshot
AQ
05/05Earnings Flash (XOMA) XOMA CORPORATION Posts Q1 Revenue $3.1M
MT
05/05XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Eve..
AQ
04/14XOMA : 2022 Letter to Stockholders
PU
04/07NEXE Up 3.9% after Reporting Initial Order of XOMA Superfoods by Purity Life Health Pro..
MT
04/05XOMA CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/28NEXE Innovations Brings Coffee Product Lines to Amazon Prime; Up 2%
MT
03/24INSIDER SELL : Xoma
MT
03/21XOMA Declares Quarterly Preferred Stock Dividends
AQ
03/11XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
03/10XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
More news
News in other languages on XOMA CORPORATION
05/05XOMA Corporation annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/05Earnings Flash (XOMA) XOMA CORPORATION affiche un chiffre d'affaires de 3,1 millions de..
04/27Kuros kann Umsatz mit Medizinprodukten im ersten Quartal verdoppeln
04/07NEXE en hausse de 3,9 % après avoir annoncé une première commande de XOMA Superfoods pa..
03/28NEXE Innovations apporte des gammes de produits de café à Amazon Prime ; hausse de 2 %.
More news
Analyst Recommendations on XOMA CORPORATION
More recommendations
Chart XOMA CORPORATION
Duration : Period :
XOMA Corporation Technical Analysis Chart | XOMA | US98419J2069 | MarketScreener
Technical analysis trends XOMA CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 17,17 $
Average target price 62,50 $
Spread / Average Target 264%
EPS Revisions
Managers and Directors
James R. Neal Chairman & Chief Executive Officer
Thomas Burns Chief Financial Officer & Senior VP-Finance
W. Denman van Ness Lead Independent Director
Jack L. Wyszomierski Independent Director
Joseph M. Limber Independent Director
Sector and Competitors
1st jan.Capi. (M$)
XOMA CORPORATION-17.65%196
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-22.98%39 423
BIONTECH SE-40.00%37 588